RE:RE:FACTS HURT FEELINGS!
Based on recent financials, it appears Elixxer is out of cash so while long terms prospects may be potentially great, where is the update on badly needed funding to survive in order to gain confidence that the company will be around long enough for the long plays to actually come to fruition. How long more will the lenders be patient?
The company needs to inform the market on drastic overhead reduction and an end to unusual transactions referenced in the recent financials like ETEA where they bought a loan in a failed company for $2.8m in nov 19 and wrote if off in Dec 19.
The fact that we dont understand this should be a worry for stockholders who want to believe this company will survive to see its Little Pharma and Friea investment pay off.
Any insights on this would be great.